search
Back to results

Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department

Primary Purpose

Gastroenteritis, Vomiting, Diarrhea

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ondansetron Oral Disintegrating Tablet
Sponsored by
The Hospital for Sick Children
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gastroenteritis

Eligibility Criteria

6 Months - 10 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Acute gastroenteritis Non-bilious and non-bloody vomiting within 4 hours of triage Diarrhea Mild to moderate dehydration Exclusion Criteria: Weight less than 8 kilograms Severe dehydration Underlying disease which might affect the assessment of hydration status (e.g., chronic renal failure, hypoalbuminemia, congestive heart failure, on diuretics) History of abdominal surgery Hypersensitivity to the drug or any components in its formulation

Sites / Locations

    Outcomes

    Primary Outcome Measures

    The proportion of children who vomit during oral rehydration therapy after receiving either 0.13-0.27 mg per kilogram of an oral disintegrating ondansetron tablet or placebo.

    Secondary Outcome Measures

    To compare in each treatment arm: mean number of episodes of vomiting, the proportion of children administered supplemental intravenous rehydration or requiring hospitalization.

    Full Information

    First Posted
    July 12, 2005
    Last Updated
    April 16, 2018
    Sponsor
    The Hospital for Sick Children
    Collaborators
    National Center for Research Resources (NCRR), GlaxoSmithKline, Ann & Robert H Lurie Children's Hospital of Chicago
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00120744
    Brief Title
    Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department
    Official Title
    Randomized Trial of the Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Acute Gastroenteritis in a Pediatric Emergency Department
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2004 (undefined)
    Primary Completion Date
    April 2005 (Actual)
    Study Completion Date
    April 2005 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    The Hospital for Sick Children
    Collaborators
    National Center for Research Resources (NCRR), GlaxoSmithKline, Ann & Robert H Lurie Children's Hospital of Chicago

    4. Oversight

    5. Study Description

    Brief Summary
    The objectives of the study were to determine whether ondansetron treatment would reduce: the amount of vomiting in the emergency department; the need for intravenous rehydration; and the need for hospitalization.
    Detailed Description
    Background: Vomiting may limit the success of oral rehydration in children with gastroenteritis and dehydration. Limited data suggest that while oral ondansetron may reduce vomiting from gastroenteritis, emergency department revisits may increase. Methods: The investigators conducted a prospective, double-blind randomized trial at a pediatric emergency department in 214 dehydrated children, aged 6 months to 10 years with gastroenteritis and mild to moderate dehydration as assessed by a dehydration score. They were randomly assigned to receive treatment with an ondansetron oral disintegrating tablet or placebo. Oral rehydration was administered according to a standard protocol. The primary outcome was the proportion of children who vomited during oral rehydration therapy. The secondary outcomes were the mean number of episodes of vomiting, and the proportion of children treated with intravenous rehydration or hospitalized.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gastroenteritis, Vomiting, Diarrhea, Dehydration

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Ondansetron Oral Disintegrating Tablet
    Primary Outcome Measure Information:
    Title
    The proportion of children who vomit during oral rehydration therapy after receiving either 0.13-0.27 mg per kilogram of an oral disintegrating ondansetron tablet or placebo.
    Secondary Outcome Measure Information:
    Title
    To compare in each treatment arm: mean number of episodes of vomiting, the proportion of children administered supplemental intravenous rehydration or requiring hospitalization.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Months
    Maximum Age & Unit of Time
    10 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Acute gastroenteritis Non-bilious and non-bloody vomiting within 4 hours of triage Diarrhea Mild to moderate dehydration Exclusion Criteria: Weight less than 8 kilograms Severe dehydration Underlying disease which might affect the assessment of hydration status (e.g., chronic renal failure, hypoalbuminemia, congestive heart failure, on diuretics) History of abdominal surgery Hypersensitivity to the drug or any components in its formulation
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Stephen B Freedman, MDCM, MSCI
    Organizational Affiliation
    The Hospital for Sick Children
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department

    We'll reach out to this number within 24 hrs